Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Winckler leaves FDA

This article was originally published in The Tan Sheet

Executive Summary

Susan Winckler, FDA chief of staff since January 2007, resigns, giving Commissioner Peggy Hamburg and the Obama administration further room to shape the agency. Winckler joined FDA as director for policy communications in September 2006, after serving as VP of policy and communications and staff counsel for the American Pharmacists Association. An August 2007 reorganization gave FDA's chief of staff a more central role and made deputy commissioners in the Office of the Commissioner report through Winckler (1"The Tan Sheet" Sept. 3, 2007)

You may also be interested in...



FDA Re-Org Makes Chief Of Staff Liaison Between Centers, Commissioner

The newly created FDA Office of the Chief of Staff will serve as the major point of contact for communication from FDA centers and offices to the commissioner, according to an Aug. 30 Federal Register notice

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS103077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel